The DOI matches its Crossref record.
Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies
Open accessAbstract
BACKGROUND: Menarche and menopause mark the onset and cessation, respectively, of ovarian activity associated with reproduction, and affect breast cancer risk. Our aim was to assess the strengths of their effects and determine whether they depend on characteristics of the tumours or the affected women. METHODS: Individual data from 117 epidemiological studies, including 118 964 women with invasive breast cancer and 306 091 without the disease, none of whom had used menopausal hormone therapy, were included in the analyses. We calculated adjusted relative risks (RRs) associated with menarche and menopause for breast cancer overall, and by tumour histology and by oestrogen receptor expression. FINDINGS: Breast cancer risk increased by a factor of 1·050 (95% CI 1·044-1·057; p<0·0001) for every year younger at menarche, and independently by a smaller amount (1·029, 1·025-1·032; p<0·0001), for every year older at menopause. Premenopausal women had a greater risk of breast cancer than postmenopausal women of an identical age (RR at age 45-54 years 1·43, 1·33-1·52, p<0·001). All three of these associations were attenuated by increasing adiposity among postmenopausal women, but did not vary materially by women's year of birth, ethnic origin, childbearing history, smoking, alcohol consumption, or hormonal contraceptive use. All three associations were stronger for lobular than for ductal tumours (p<0·006 for each comparison). The effect of menopause in women of an identical age and trends by age at menopause were stronger for oestrogen receptor-positive disease than for oestrogen receptor-negative disease (p<0·01 for both comparisons). INTERPRETATION: The effects of menarche and menopause on breast cancer risk might not be acting merely by lengthening women's total number of reproductive years. Endogenous ovarian hormones are more relevant for oestrogen receptor-positive disease than for oestrogen receptor-negative disease and for lobular than for ductal tumours. FUNDING: Cancer Research UK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The global burden of women's cancers: a grand challenge in global health
Ginsburg, O., Bray, F., Coleman, M. P., Vanderpuye, V., Eniu, A., Kotha, S. R., Sarker, M., Huong, T. T., Allemani, C., Dvaladze, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31392-7 · Cited by 1,127
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Study, T. L. C., Day, F. R., The InterAct Consortium, kConFab/AOCS Investigators, Endometrial Cancer Association Consortium, Ovarian Cancer Association Consortium, PRACTICAL consortium, Thompson, D. J., Helgason, H., Chasman, D. I., et al. (2017) · Nature Genetics · doi:10.1038/ng.3841 · Cited by 587
The PRACTICAL Consortium, Day, F. R., kConFab Investigators, AOCS Investigators, Scotland, G., EPIC-InterAct Consortium, Study, L. C., Ruth, K. S., Thompson, D. J., Lunetta, K. L., et al. (2015) · Nature Genetics · doi:10.1038/ng.3412 · Cited by 402
Qi, G., & Chatterjee, N. (2019) · Nature Communications · doi:10.1038/s41467-019-09432-2 · Cited by 207
Burgess, S., Thompson, D. J., Rees, J. M. B., Day, F. R., Perry, J. R., & Ong, K. K. (2017) · Genetics · doi:10.1534/genetics.117.300191 · Cited by 197
Menopausal hormone therapy for the management of osteoporosis
Gosset, A., Pouillès, J.-M., & Trémollieres, F. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101551 · Cited by 193
Incidence of breast cancer in the life span study of atomic bomb survivors: 1958-2009
Brenner, A. V., Preston, D. L., Sakata, R., Sugiyama, H., de Gonzalez, A. B., French, B., Utada, M., Cahoon, E. K., Sadakane, A., Ozasa, K., et al. (2018) · Radiation Research · doi:10.1667/rr15015.1 · Cited by 113
Sehgal, R., Markov, Y., Qin, C., Meer, M., Hadley, C., Shadyab, A. H., Casanova, R., Manson, J. E., Bhatti, P., Moore, A. Z., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00958-3 · Cited by 79
RANKL/RANK: from bone loss to the prevention of breast cancer
Sigl, V., Jones, L. P., & Penninger, J. M. (2016) · Open Biology · doi:10.1098/rsob.160230 · Cited by 76
Tin Tin, S., Reeves, G. K., & Key, T. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01392-z · Cited by 71
Chen, X., Liu, Y., Sun, X., Yin, Z., Li, H., Liu, X., Zhang, D., Cheng, C., Liu, L., Liu, F., et al. (2019) · Menopause · doi:10.1097/gme.0000000000001289 · Cited by 68
Légaré, S., & Basik, M. (2016) · Molecular Endocrinology · doi:10.1210/me.2016-1072 · Cited by 63
Age of menarche and time to pregnancy
Guldbrandsen, K., Hakonsen, L. B., Ernst, A., Toft, G., Lyngso, J., Olsen, J., & Ramlau-Hansen, C. H. (2014) · Human Reproduction · doi:10.1093/humrep/deu153 · Cited by 58
Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer
Kumar, N., Gulati, H. K., Sharma, A., Heer, S., Jassal, A. K., Arora, L., Kaur, S., Singh, A., Bhagat, K., Kaur, A., et al. (2021) · Molecular Diversity · doi:10.1007/s11030-020-10133-y · Cited by 37
Robinson, O., Lau, C. E., Joo, S., Andrusaityte, S., Borras, E., de Prado-Bert, P., Chatzi, L., Keun, H. C., Grazuleviciene, R., Gutzkow, K. B., et al. (2023) · eLife · doi:10.7554/elife.85104 · Cited by 20
Metadata
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 13
- Issue
- 11
- Pages
- 1141-1151
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2165413853
- Cited by
- 1,160
- References
- 0
- FWCI
- 13.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
